Lacrisert
FDA Approves Retinal Implant for Rare Genetic Eye Disease »
"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
Read the FDA Approves Retinal Implant for Rare Genetic Eye Disease article »
Lacrisert
SIDE EFFECTS
The following adverse reactions have been reported in patients treated with LACRISERT (cellulose) , but were in most instances mild and transient:
Transient blurring of vision (See PRECAUTIONS)
Ocular discomfort or irritation
Matting or stickiness of eyelashes
Photophobia
Hypersensitivity
Edema of the eyelids
Hyperemia
Read the Lacrisert (cellulose) Side Effects Center for a complete guide to possible side effects »
DRUG INTERACTIONS
Application of hydroxypropyl cellulose ophthalmic inserts to the eyes of unanesthetized rabbits immediately prior to or two hours before instilling pilocarpine, proparacaine HCl (0.5%), or phenylephrine (5%) did not markedly alter the magnitude and/or duration of the miotic, local corneal anesthetic, or mydriatic activity, respectively, of these agents. Under various treatment schedules, the anti-inflammatory effect of ocularly instilled dexamethasone (0.1%) in unanesthetized rabbits with primary uveitis was not affected by the presence of hydroxypropyl cellulose inserts.
Last reviewed on RxList: 3/13/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Lacrisert Information
Lacrisert - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.






